Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis

Ralph Chebib; Loic Verlingue; Nathalie Cozic; Matthieu Faron; Pascal Burtin; Valérie Boige; Antoine Hollebecque; David Malka

doi:10.1053/j.seminoncol.2017.07.004

Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis

Ralph Chebib, Loic Verlingue, Nathalie Cozic, Matthieu Faron, Pascal Burtin, Valérie Boige, Antoine Hollebecque, David Malka

Research output: Contribution to journal › Review article › peer-review

18 Scopus citations

Abstract

The last two decades have seen intensive efforts devoted to the development of compounds that target angiogenesis for the treatment of metastatic colorectal cancer (mCRC). In this review, we describe supporting evidence and ongoing development of angiogenesis inhibitors in the second-line treatment of mCRC, and summarize relevant randomized trials to help therapeutic decision-making in daily practice.

Original language	English
Pages (from-to)	114-128
Number of pages	15
Journal	Seminars in Oncology
Volume	44
Issue number	2
DOIs	https://doi.org/10.1053/j.seminoncol.2017.07.004
State	Published - Apr 2017
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2017 Elsevier Inc.

Funding

Dr Verlingue reports personal fees from Adaptherapy, outside the submitted work. Dr Boige reports grants, personal fees and non-financial support from Merck Serono, personal fees and non-financial support from Bayer, personal fees and non-financial support from Amgen, personal fees and non-financial support from Sanofi, personal fees from Daiichi Sankyo, personal fees from Novartis, personal fees from Roche, personal fees from Prestizia, outside the submitted work. Dr Malka reports personal fees and non-financial support from Roche, personal fees from Amgen, personal fees and non-financial support from Sanofi-Aventis, personal fees from Celgene, personal fees from Teva, personal fees from Boehringer-Ingelheim, personal fees from Menarini, personal fees and non-financial support from Merck Serono, personal fees from Bayer, personal fees from Lilly, personal fees from MSD, outside the submitted work. Drs Chebib, Burtin, and Faron and Nathalie Cozic had nothing to declare.

Funders	Funder number
Amgen
Eli Lilly and Company
Bayer
Merck
Novartis
Roche
Sanofi
EMD Serono
Teva Pharmaceutical Industries
Celgene
Meso Scale Diagnostics
Sanofi-Aventis Korea Company
Daiichi Sankyo Company
Fondazione Internazionale Menarini

Keywords

Angiogenesis inhibitors
Colorectal cancer
Pooled analysis
Second-line chemotherapy
Systematic review

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1053/j.seminoncol.2017.07.004

Cite this

@article{3952d928231e4e568559c92c56b465f7,

title = "Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis",

abstract = "The last two decades have seen intensive efforts devoted to the development of compounds that target angiogenesis for the treatment of metastatic colorectal cancer (mCRC). In this review, we describe supporting evidence and ongoing development of angiogenesis inhibitors in the second-line treatment of mCRC, and summarize relevant randomized trials to help therapeutic decision-making in daily practice.",

keywords = "Angiogenesis inhibitors, Colorectal cancer, Pooled analysis, Second-line chemotherapy, Systematic review",

author = "Ralph Chebib and Loic Verlingue and Nathalie Cozic and Matthieu Faron and Pascal Burtin and Val{\'e}rie Boige and Antoine Hollebecque and David Malka",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Inc.",

year = "2017",

month = apr,

doi = "10.1053/j.seminoncol.2017.07.004",

language = "אנגלית",

volume = "44",

pages = "114--128",

journal = "Seminars in Oncology",

issn = "0093-7754",

publisher = "W.B. Saunders",

number = "2",

}

TY - JOUR

T1 - Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer

T2 - A systematic review and pooled analysis

AU - Chebib, Ralph

AU - Verlingue, Loic

AU - Cozic, Nathalie

AU - Faron, Matthieu

AU - Burtin, Pascal

AU - Boige, Valérie

AU - Hollebecque, Antoine

AU - Malka, David

PY - 2017/4

Y1 - 2017/4

N2 - The last two decades have seen intensive efforts devoted to the development of compounds that target angiogenesis for the treatment of metastatic colorectal cancer (mCRC). In this review, we describe supporting evidence and ongoing development of angiogenesis inhibitors in the second-line treatment of mCRC, and summarize relevant randomized trials to help therapeutic decision-making in daily practice.

AB - The last two decades have seen intensive efforts devoted to the development of compounds that target angiogenesis for the treatment of metastatic colorectal cancer (mCRC). In this review, we describe supporting evidence and ongoing development of angiogenesis inhibitors in the second-line treatment of mCRC, and summarize relevant randomized trials to help therapeutic decision-making in daily practice.

KW - Angiogenesis inhibitors

KW - Colorectal cancer

KW - Pooled analysis

KW - Second-line chemotherapy

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=85028073533&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2017.07.004

DO - 10.1053/j.seminoncol.2017.07.004

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 28923209

AN - SCOPUS:85028073533

SN - 0093-7754

VL - 44

SP - 114

EP - 128

JO - Seminars in Oncology

JF - Seminars in Oncology

IS - 2

ER -

Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis

Abstract

Bibliographical note

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this